17 December 2019 - TLV has developed a new health economic knowledge base for the regions of the drug Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of multiple myeloma relapses.

TLV has previously evaluated Kyprolis in combination with Revlimid and dexamethasone and also Kyprolis in combination with dexamethasone alone. 

Now there is data with longer follow-up time from the clinical study of Kyprolis in combination with Revlimid and dexamethasone that TLV has used in this new evaluation.

Read TLV News [Swedish]